SALT LAKE CITY, Oct. 28, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced it will hold a conference call on Tuesday, November 9, 2010 at 4:30 p.m. ET (1:30 p.m. PT) to discuss financial results for its fiscal first quarter 2011 ended September 30, 2010, and plans for its upcoming two-arm Phase 2b clinical trial of Azixa, its lead clinical development candidate, in front-line glioblastoma multiforme (GBM). The conference call will be hosted by Adrian Hobden, Ph.D., President and Chief Executive Officer, and Robert Lollini, Chief Financial Officer and Treasurer. To participate, please dial 1-877-312-5447 (USA) or 1-253-237-1129 (International). To access the live web cast please visit the Investor Relations section on the corporate web site at www.myrexis.com. A replay of the conference call will be available beginning November 9, 2010 at 7:30 p.m. ET (4:30 p.m. PT) and ending on November 16, 2010 by dialing 1-800-642-1687 (USA) or 1-706-645-9291 (International), Conference ID: 20347595. A replay of the webcast will also be available on the corporate website for one month, through December 9, 2010. About Azixa (verubulin or MPC-6827) Azixa is the lead product candidate under development by Myrexis for the treatment of primary brain cancers. Azixa is a novel small molecule that acts as a microtubule destabilizing agent, causing an arrest of cell division with subsequent programmed cell death, or apoptosis, in cancer cells. Several currently marketed clinically effective drugs share the identical mechanism of action. Importantly, however, Azixa has two unique, distinguishing characteristics. In non-clinical studies, Azixa has demonstrated the ability to effectively cross the blood-brain barrier and accumulate in the brain at levels as much as 30 times that measured in the plasma. In addition, Azixa does not appear to be subject to multiple drug resistance (MDR) mechanisms.